ClinicalTrials.gg
Status unknownNCT03563235CSOPOPWXJGUpdated Feb 26, 2019

Clinical Study on Treatment of Postmenopausal Osteoporosis (Kidney Deficiency and Blood Stasis Syndrome) With Xulin Jiangu Granules

An Early Phase 1 interventional study of Xulin Jiangu granules and Calcitriol capsules in Postmenopausal Osteoporoses, sponsored by Fujian Academy of Traditional Chinese Medicine. Status unknown at 1 site in China. Open to female participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by Fujian Academy of Traditional Chinese Medicine · Early Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2019), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies in Osteoporosis, Postmenopausal with a site in China — 1 open to participants now, 1 under way, none of them phase 3. Osteoporosis, Postmenopausal · China.

Planned enrollment
17th of 21
60 · median 148
Started
2019
with 5 others
Phase 1
5 of 25
none open now
Registered
10th of 25
by date
Lead sponsor
3 of 25
Fujian Academy of Traditional Chinese Medicine

Among the 25 studies in Osteoporosis, Postmenopausal with a site in China, this one is the 17th largest by planned enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2019, is one of 5 in phase 1, and was the 10th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 25 studies in Osteoporosis, Postmenopausal with a site in China is open now. Recruiting first, the newest first:

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Osteoporosis, Postmenopausal with a site in China, or all of them as a file.
02

Study summary

Osteoporosis is a common senile disease with a high incidence. The Chinese medicine differentiation treatment has small side effects and can be taken for a long time, which has certain advantages. This project adopts the experience of the person in charge of the project-Xulin Jiangu Granules and clinically collects patients with postmenopausal osteoporosis (kidney deficiency and blood stasis syndrome).

Read the detailed description

Randomized control method was used to observe the clinical efficacy of the treatment of postmenopausal osteoporosis (kidney deficiency and blood stasis syndrome) with jiujian jiangu granules, combined with the gene expression of bone metabolism markers BALP, PINP, TRACP and S-CTX, and RANK, RANKL and OPG Detection, compared with the control group of ossification trihydrate capsules, to explore the mechanism of the treatment of postmenopausal osteoporosis by the continued Xulin Jiangu granules, and lay the foundation for the development of new drugs.

03

Conditions studied

  • Postmenopausal Osteoporoses

Keywords

  • Osteoporosis
  • kidney deficiency and blood stasis syndrome
  • Xuling Jiangu Granules
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 2 years prior and met the diagnostic criteria for osteoporosis according to the "clinical practice guidelines of traditional medicine for primary osteoporosis
  • met the CM diagnostic criteria according to "Syndrome Differentiation in Modern Research of Traditional Chinese Medicine

Exclusion criteria

Exclusion Criteria:

  • patients who did not meet the diagnostic criteria for osteoporosis or CM standards
  • patients with rheumatoid arthritis, diabetes, secondary osteoporosis due to hyperthyroidism, and severe cardiovascular or cerebrovascular diseases
  • patients with abnormal liver and/or Shen function test results
  • patients with osteoporosis who had received treatment with CM within the last month, hormone replacement therapy and calcitonin within the past three months, or bisphosphonates for 15 consecutive days within the past 6 months.
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Xulin Jiangu granules

    Xulin Jiangu granule 15g tablet by mouth every 6 hour for 6 months

    Drug: Xulin Jiangu granules · Drug: Calcitriol capsules

  • Active comparator
    Calcitriol capsules

    Calcitriol capsules tablets 0.25 ug by mouth every 6 hour for 6 months

    Drug: Xulin Jiangu granules · Drug: Calcitriol capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Bone density(BMD)

    BMD is the gold standard of oeteoporosis

    Time frame: Xulin Jiangu treats for up to six months

07

Study locations

1 site
  • Fujian Academy of Trational Chiness Medicine
    Fuzhou, Fujian 350003, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2019; primary completion for Sep 2021, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2018
First posted
Jun 20, 2018
StartEst.
Sep 1, 2019
Primary completionEst.
Sep 30, 2021
CompletionEst.
Dec 31, 2021
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03563235
Lead sponsor
Fujian Academy of Traditional Chinese Medicine
Responsible party
Sponsor
First posted
Jun 20, 2018
Start date
Sep 1, 2019 (estimated)
Primary completion
Sep 30, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Feb 26, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion